Overview
- GAP’s Bio‑Hermes‑002 study has enrolled 883 of 1,000 participants across 25 sites in the UK, US and Canada, with more than 360 already completing the test.
- The trial uses a finger‑prick plasma separation card that can be stored without refrigeration and shipped at ambient temperature for lab analysis.
- Investigators will assess pTau217, GFAP and NfL in capillary blood and benchmark results against PET, MRI and other blood and digital measures.
- Separately, EU pilots of the 2D‑BioPAD device in Finland, Greece and Germany are testing a graphene sensor designed to read up to five biomarkers from a small blood sample in about 30 minutes.
- Neither approach is ready for routine screening; 2D‑BioPAD expects performance comparisons by end‑2026, and Bio‑Hermes‑002 targets completion in 2028 as early therapies increase the value of detecting disease sooner.